Publication

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment

Oosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Oude Munnink, T. H., Lub-de Hooge, M. N., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., Scherer, S. J., Sluiter, W. J., Dierckx, R. A., Bongaerts, A. H. H., Gietema, J. A. & de Vries, E. G. E., Jan-2015, In : Journal of Nuclear Medicine. 56, 1, p. 63-69 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

    Final publisher's version, 877 KB, PDF document

DOI

UNLABELLED: No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.

METHODS: Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n = 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n = 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression.

RESULTS: (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV(max) of -47.0% (range, -84.7 to +20.0%; P < 0.0001) at 2 wk and an additional -9.7% (range, -44.8 to +38.9%; P = 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV(max) was -14.3% at 2 wk (range, -80.4 to +269.9; P = 0.006), but at 6 wk the mean change in tumor SUV(max) was +72.6% (range, -46.4 to +236%; P < 0.0001) above baseline. SUV(max) was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV(max) greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00).

CONCLUSION: Tumor uptake of (89)Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV(max) was associated with longer time to progression.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalJournal of Nuclear Medicine
Volume56
Issue number1
Publication statusPublished - Jan-2015

    Keywords

  • renal cell carcinoma, molecular imaging, positron emission tomography, bevacizumab, sunitinib, ENDOTHELIAL GROWTH-FACTOR, METASTATIC BREAST-CANCER, PHASE-III TRIAL, INTERFERON-ALPHA, ANTI-VEGF, BEVACIZUMAB, SUNITINIB, EFFICACY, IN-111-BEVACIZUMAB, BIODISTRIBUTION

ID: 16223735